Tamoxifen: long-term benefit in ER-positive breast cancer

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1584, 2007-01, pp. : 22-22

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer: A UK Perspective Considering Duration of Benefit, Long-Term Toxicity and Pattern of Recurrence

By Hall Peter S.   Hulme Claire   McCabe Christopher   Oluboyede Yemi   Round Jeff   Cameron David A.  

PharmacoEconomics, Vol. 29, Iss. 5, 2011-05 ,pp. : 415-432

Adis International

Access to resources Recommend Favorite

Breast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen

By Brown Karen  

Expert Opinion on Drug Safety, Vol. 1, Iss. 3, 2002-09 ,pp. : 253-267

Informa Healthcare

Access to resources Recommend Favorite

No long-term QOL benefit for CRT

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 637, 2011-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Long-term female hormone use a risk factor for breast cancer?

By  

Reactions Weekly, Vol. 1, Iss. 1102, 2006-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Sexual functioning and mood not affected by long-term tamoxifen

By  

Inpharma, Vol. 1, Iss. 1282, 2001-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite